Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published April 14, 2009 | Published + Supplemental Material
Journal Article Open

Tumor detection and elimination by a targeted gallium corrole

Abstract

Sulfonated gallium(III) corroles are intensely fluorescent macrocyclic compounds that spontaneously assemble with carrier proteins to undergo cell entry. We report in vivo imaging and therapeutic efficacy of a tumor-targeted corrole noncovalently assembled with a heregulin-modified protein directed at the human epidermal growth factor receptor (HER). Systemic delivery of this protein-corrole complex results in tumor accumulation, which can be visualized in vivo owing to intensely red corrole fluorescence. Targeted delivery in vivo leads to tumor cell death while normal tissue is spared. These findings contrast with the effects of doxorubicin, which can elicit cardiac damage during therapy and required direct intratumoral injection to yield similar levels of tumor shrinkage compared with the systemically delivered corrole. The targeted complex ablated tumors at >5 times a lower dose than untargeted systemic doxorubicin, and the corrole did not damage heart tissue. Complexes remained intact in serum and the carrier protein elicited no detectable immunogenicity. The sulfonated gallium(III) corrole functions both for tumor detection and intervention with safety and targeting advantages over standard chemotherapeutic agents.

Additional Information

© 2009 by the National Academy of Sciences. Contributed by Harry B. Gray, February 15, 2009 (received for review December 18, 2008). We thank Krishnan Ramanujan for helpful feedback and critical review of this work; Kolja Wawrowsky (Cedars-Sinai Medical Center Confocal Core Facility) and Sarah Hamm-Alvarez and Jiansong Xie (University of Southern California Department of Pharmaceutical Sciences) for assistance with microscopic imaging; and Renata Stripecke and Emmanuelle Faure-Kumar (UCLA Vector Core) for provision of adenovirus and lentivirus vectors. This work was supported by National Institutes of Health (NIH) Grants R21 CA116014 and R01 CA102126, Department of Defense Grant BC050662, Susan G. Komen Breast Cancer Foundation Grant BCTR0201194, and a Donna and Jesse Garber Award (all to L.K.M.-K.), and by the U.S. Navy Bureau of Medicine and Surgery (D.L.F.). Work performed at the Technion-Israel Institute of Technology was supported by grants from the Gurwin and Binational Science foundations (to Z.G.). Research at California Institute of Technology was supported by grants from NIH and the National Science Foundation (to H.B.G.).

Attached Files

Published - Agadjanian2009p2046P_Natl_Acad_Sci_Usa.pdf

Supplemental Material - SUPPAgadjanian2009p2046P_Natl_Acad_Sci_Usa.pdf

Files

SUPPAgadjanian2009p2046P_Natl_Acad_Sci_Usa.pdf
Files (1.5 MB)
Name Size Download all
md5:3d050a4cf3cacb4b62f9fee01f84901a
411.2 kB Preview Download
md5:29281ea11319299045eaa72b09967eb2
1.1 MB Preview Download

Additional details

Created:
August 21, 2023
Modified:
October 18, 2023